IL17A and psoriasis: Consistent with the fact that IL-17 has a pathogenic role in psoriasis by inducing pro-inflammatory molecules [67], treatment with an anti-IL-17A antibody, such as secukinumab, has shown sustained efficacy in psoriatic arthritis [68,69,70].